查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
骨髓惡性腫瘤檢測市場 - 全球和區域分析：按產品、平台、疾病、最終用戶、區域 - 分析和預測（2024-2033）
市場調查報告書
商品編碼
1522696

骨髓惡性腫瘤檢測市場 - 全球和區域分析：按產品、平台、疾病、最終用戶、區域 - 分析和預測（2024-2033）

Hematologic Malignancies Testing Market - A Global and Regional Analysis: Focus on Product, Platform, Disease, End User, and Region - Analysis and Forecast, 2024-2033
出版日期: | 出版商: BIS Research | 英文 258 Pages | 商品交期: 1-5個工作天內

價格

2023年全球骨髓惡性腫瘤檢測市場規模為35.463億美元。

預計到 2033 年，市場規模將達到 135.095 億美元，2024-2033 年預測期間複合年成長率為 14.09%。骨髓惡性腫瘤檢測市場專注於檢測和監測白血病、淋巴瘤和骨髓瘤等血癌的診斷工具和技術。隨著這些癌症盛行率的增加和診斷方法的進步，市場正在迅速擴大。關鍵技術包括次世代定序（NGS）、聚合酵素鏈鎖反應（PCR）、流式細胞技術和免疫組織化學。這些工具對於準確診斷、預後預測和治療計劃至關重要。

骨髓惡性腫瘤檢測市場的成長受到多種因素的推動，例如血液腫瘤負擔的增加、研究出版物數量的增加以及骨髓惡性腫瘤檢測臨床試驗數量的增加，導致對骨髓惡性腫瘤檢測和產品的需求增加正在被拖走。此外，對早期檢測和早期治療的資金和社區支持的增加創造了對骨髓惡性腫瘤檢測套組和服務的需求，並且骨髓惡性腫瘤了更有效和創新的檢測，這與套件的開發有關。此外，這些補充品透過各種分銷管道（例如線上平台和零售店）提供，進一步促進了市場擴張和接觸全球消費者。

主要市場統計數據
預測期 2024-2033
2024年評估 41.2億美元
2033 年預測 135億美元
複合年成長率 14.09%

骨髓惡性腫瘤檢測市場專注於用於識別和監測白血病、淋巴瘤和骨髓瘤等血癌的診斷工具和技術。由於這些癌症盛行率的上升、診斷技術的進步以及對早期檢測和個人化醫療的關注，該市場正在顯著成長。全球骨髓惡性腫瘤盛行率的上升凸顯了醫療保健領域顯著成長的潛力。 GLOBOCAN 預測，到 2050 年，這些癌症將比 2022 年增加 56.37%。隨著這些疾病在各個地區變得越來越普遍，對先進診斷工具、有效治療性介入和全面支持性護理服務的需求預計將增加，以滿足日益成長的醫療保健需求。

血液癌症治療中對個人化腫瘤學和標靶治療的日益重視，增加了骨髓惡性腫瘤檢測中伴同性診斷的需求。政府的核准和報銷政策促進了臨床採用，並為融入標準腫瘤護理鋪平了道路。隨著人們對癌症早期檢測及其非侵入性診斷方法的認知不斷增強，骨髓惡性腫瘤檢測市場預計在未來幾年將進一步擴大和多樣化。

該報告研究了全球骨髓惡性腫瘤檢測市場，並提供了市場概述，包括按產品、平台、疾病、最終用戶和地區分類的趨勢，以及參與該市場的公司概況。

目錄

第1章 全球骨髓惡性腫瘤檢測市場：市場概述

第2章全球骨髓惡性腫瘤檢測市場：產業分析

  • 主要趨勢：當前和未來的影響評估
  • 法律規範
  • COVID-19 對癌症診斷市場的影響
  • 供應鏈分析
  • 價格分析
  • 不同參數對造血系統惡性檢測的比較分析

第3章全球骨髓惡性腫瘤檢測市場：市場動態

  • 影響分析
  • 市場促進因素
  • 市場限制因素
  • 市場機會

第4章 全球骨髓惡性腫瘤檢測市場（依產品）

  • 產品概要
  • 依產品

第5章 全球骨髓惡性腫瘤檢測市場（依平台）

  • 平台概覽
  • 按平台

第6章 全球骨髓惡性腫瘤檢測市場（依疾病分類）

  • 疾病概述
  • 按疾病分類

第7章全球骨髓惡性腫瘤檢測市場（依最終用戶）

  • 最終用戶概述
  • 按最終用戶

第8章 全球骨髓惡性腫瘤檢測市場（按地區）

  • 區域概況
  • 促進因素和限制因素
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第9章全球骨髓惡性腫瘤檢測市場 - 競爭基準化分析和公司概況

  • 關鍵策略和發展
  • 市場佔有率
  • 公司簡介
    • Abbott Laboratories
    • Adaptive Biotechnologies
    • ARUP Laboratories
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • ICON plc
    • Illumina, Inc.
    • Invitae Corporation
    • Invivoscribe Inc.
    • Laboratory Corporation of America Holdings
    • NeoGenomics Laboratories
    • OHSU's Knight Diagnostic Laboratories
    • QIAGEN NV
    • Quest Diagnostics
    • Sysmex Corporation
    • Tempus Labs, Inc
    • Bio-Techne
    • DiaSorin SpA
    • Foundation Medicine, Inc.
    • Thermo Fisher Scientific, Inc.
    • ELITech Group
    • Vela Diagnostics
    • Amoy Diagnostics Co., Ltd.
    • Integrated DNA Technologies, Inc.

第10章調查方法

Product Code: BHP0771SC

Global Hematologic Malignancies Testing Market Industry Overview

The global hematologic malignancies testing market was valued at $3,546.3 million in 2023 and is expected to reach $13,509.5 million by 2033, growing at a CAGR of 14.09% during the forecast period 2024-2033. The hematologic malignancies testing market focuses on diagnostic tools and technologies for detecting and monitoring blood cancers such as leukemia, lymphoma, and myeloma. With the growing incidence of these cancers and advancements in diagnostic methods, the market is rapidly expanding. Key technologies include next-generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, and immunohistochemistry. These tools are crucial for accurate diagnosis, prognosis, and treatment planning.

The growth of the hematologic malignancies testing market is driven by several factors, such as the rising burden of hematological cancer, growing research publications, and clinical trials in hematologic malignancies testing, leading to increased demand for hematologic malignancies tests and products. Additionally, increased funding and community support for early detection and treatment create a demand for hematological malignancy testing kits and services, and continuous advancements in hematologic malignancy have led to the development of more effective and innovative tests and kits. Moreover, the expanding availability of these supplements through various distribution channels, including online platforms and retail stores, has further facilitated market expansion and accessibility to consumers worldwide.

KEY MARKET STATISTICS
Forecast Period2024 - 2033
2024 Evaluation$4.12 Billion
2033 Forecast$13.50 Billion
CAGR14.09%

Market Introduction

The hematological malignancies testing market focuses on diagnostic tools and technologies used to identify and monitor cancers of the blood, including leukemia, lymphoma, and myeloma. This market is growing significantly, driven by the rising incidence of these cancers, technological advancements in diagnostics, and a focus on early detection and personalized medicine. The rising prevalence of hematologic malignancies globally highlights substantial growth potential in the healthcare sector. GLOBOCAN projects a 56.37% increase in these cancers by 2050 compared to 2022. As these diseases become more widespread across various regions, there is expected to be a growing need for advanced diagnostic tools, effective therapeutic interventions, and comprehensive supportive care services to meet the increasing healthcare demands.

The growing emphasis on personalized oncology and targeted therapies for hematological cancer treatment has fuelled demand for companion diagnostics tests on hematologic malignancies testing. Facilitation of its adoption in clinical practices by government approvals and reimbursement policies has paved the way for their integration into standard oncology care. As awareness about early cancer detection and its non-invasive diagnostic method continues to rise, the hematologic malignancies testing market is poised for further expansion and diversification in the coming years.

Industrial Impact

The growth of the hematologic malignancies testing market has not only provided relief to individuals having cancer symptoms but has also had a notable industrial impact. Manufacturers and suppliers of these products have witnessed increased demand, leading to expanded production capacities and job creation within the industry.

Market Segmentation:

Segmentation 1: by Product

  • Kits
  • Services

Services Segment to Dominate the Hematologic Malignancies Testing Market (by Product)

The services segment is expected to dominate the hematologic malignancies testing market by product. This is primarily due to the complexity of tests and the advanced technology required in performing the hematologic malignancies testing. The service providers not only perform the tests but also handle data analysis.

Segmentation 2: by Platform

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Fluorescence In-Situ Hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Flow Cytometry
  • Other Platforms

Polymerase Chain Reaction (PCR) Segment to Dominate the Hematologic Malignancies Testing Market (by Platform)

The polymerase chain reaction (PCR) segment is anticipated to dominate the hematologic malignancies testing market by platform. This predominance results from its rapid turnaround times and high sensitivity and specificity, which are essential for detecting and quantifying specific genetic changes linked to various hematologic cancers.

Segmentation 3: by Disease

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Myelodysplastic Syndrome

Leukemia Segment to Dominate the Hematologic Malignancies Testing Market (by Diseases)

The leukemia segment is expected to dominate the hematologic malignancies testing market based on diseases. This predominance results from the high prevalence and incidence of leukemia, which elevates the demand for diagnostic testing. The complexity of leukemia, with its various subtypes requiring specific diagnostic methods, further intensifies the need for comprehensive testing.

Segmentation 4: by End User

  • Specialty Clinics and Hospitals
  • Diagnostic Laboratories
  • Reference Laboratories

Specialty Clinics and Hospitals Segment to Dominate the Hematologic Malignancies Testing Market (by End User)

The specialty clinics and hospitals segment of the hematologic malignancies testing market by end user is expected to lead the market. This leadership stems from their integrated patient care models that ensure timely and coordinated diagnosis and treatment, which are critical for hematologic malignancies. These facilities feature advanced infrastructure to support sophisticated diagnostic tools and employ specialized personnel essential for interpreting complex test results.

Segmentation 5: by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Denmark
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • South Korea
    • Australia
    • Singapore
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Middle East and Africa
    • K.S.A.
    • U.A.E.
    • South Africa
    • Rest-of-Middle East and Africa

The North America region is positioned to hold a significant share of the global market for several compelling reasons. North America's growth has been driven by high rates of hematologic malignancies in the U.S. and Canada. Europe and Asia-Pacific are expected to see substantial growth, with China showing strong performance and increased adoption in Japan and India. Strategic partnerships in Latin America and other regions are tackling infrastructure challenges, thereby creating opportunities for manufacturers and service providers worldwide.

Recent Developments in the Hematologic Malignancies Testing Market

  • In May 2024, Bruker Corporation acquired ELITech Group with an expectation of generating revenue of $100 million by ELITech Group from the remainder of 2024.
  • In April 2024, QIAGEN N.V. announced the launch of the QIAseq Targeted RNA-seq Panel for T-cell receptors, emphasizing their critical role in the adaptive immune system's function of recognizing and eliminating abnormal cells, including cancer cells.
  • In February 2024, Precipio, Inc. announced the signing of a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. Under the agreement, Cardinal Health will market and distribute Precipio's HemeScreen portfolio of molecular assays to its customer base, primarily comprising acute healthcare systems (hospital networks), reference laboratories, and physician-owned laboratories.
  • In January 2024, Illumina, Inc. announced it signed an agreement with Janssen Research & Development, LLC (Janssen). This collaboration marks the first step in developing Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA) to enhance understanding of disease persistence or recurrence after clinical intervention.

Demand - Drivers, Challenges, and Opportunities

Market Demand Drivers:

Rising Incidence of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, and Leukemia Facilitating the Demand for Hematologic Malignancy Testing Kits and Services: The increasing prevalence of hematologic malignancies globally highlights significant growth potential in the healthcare sector. GLOBOCAN projects a 56.37% rise in these cancers by 2050 compared to 2022. As these diseases become more common across various regions, there will be a critical need for advanced diagnostic tools, effective therapeutic interventions, and comprehensive supportive care services to meet the growing healthcare demands.

Market Challenges:

Challenges in Integrating NGS into Clinical Practice for Hematologic Malignancies: Integrating next-generation sequencing (NGS) into clinical diagnostics for hematologic malignancies encounters significant challenges, hindering market growth. Despite its potential to transform disease classification, risk assessment, and treatment decisions, the complexity of interpreting and applying NGS-derived molecular genetic data remains a major obstacle. The phenotypic and genetic diversity of acute and chronic myeloid malignancies requires advanced expertise and sophisticated bioinformatic tools to differentiate clinically relevant driver mutations from incidental passenger mutations.

Market Opportunities:

Leveraging AI for Enhanced Diagnostics in the Hematologic Malignancies Testing Market: Integrating artificial intelligence (AI) into the diagnosis of hematologic malignancies offers a significant business opportunity in the global hematologic malignancies testing market. Researchers at the Ohio State University Comprehensive Cancer Center have demonstrated AI's potential to accurately differentiate between two rare blood cancers, prefibrotic primary myelofibrosis (prePMF) and essential thrombocythemia (ET). This distinction is crucial for determining appropriate treatment and enrolling patients in clinical trials, a task that traditional diagnostic methods find challenging.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The global hematologic malignancies testing market has been segmented based on various categories, such as products, platforms, diseases, end users, and regions.

Growth/Marketing Strategy: Partnerships, alliances, funding, and business expansions together accounted for the maximum number of key developments of the total developments in the 'Hematologic Malignancies Testing Market' between January 2020 and May 2024.

Competitive Strategy: The global hematologic malignancies testing market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the hematologic malignancies testing market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2023. A historical year analysis has been done for the period FY2019-FY2022. The market size has been estimated for FY2023 and projected for the period FY2024-FY2033.
  • The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of hematologic malignancies testing.
  • The market contribution of hematologic malignancy testing anticipated to be launched in the future has been calculated based on the historical analysis of the solutions.
  • Revenues of the companies have been referenced from their annual reports for FY2022 and FY2023.
  • The market has been mapped based on the available hematologic malignancies testing products. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in hematologic malignancies testing, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of the report's segmentation and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of the different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players of the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Based on product, the hematologic malignancies testing market service segment players leading the market captured around 58.36% of the market's presence as of 2023. Kits, on the other hand, accounted for approximately 41.64% of the market presence in 2023, respectively.

Some prominent names established in this market are:

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • ARUP Laboratories
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • ICON plc
  • Illumina, Inc.
  • Invitae Corporation
  • Invivoscribe Inc.
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories
  • OHSU's Knight Diagnostic Laboratories
  • QIAGEN N.V.
  • Quest Diagnostics
  • Sysmex Corporation
  • Tempus Labs, Inc
  • Bio-Techne
  • DiaSorin S.p.A
  • Foundation Medicine, Inc.
  • Thermo Fisher Scientific, Inc.
  • ELITech Group
  • Vela Diagnostics
  • Amoy Diagnostics Co., Ltd.
  • Integrated DNA Technologies, Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Global Hematologic Malignancies Testing Market: Market Overview

  • 1.1 Introduction
  • 1.2 Types of Hematologic Malignancies Diagnostic Tests
  • 1.3 Market Footprint and Growth Potential

2 Global Hematologic Malignancies Testing Market: Industry Analysis

  • 2.1 Key Trends: Current and Future Impact Assessment
    • 2.1.1 Growing Utilization of Next-Generation Sequencing and Artificial Intelligence in Hematologic Malignancies Testing
    • 2.1.2 Increasing Partnerships, Alliances, and Business Expansions among Key Players
  • 2.2 Regulatory Framework
    • 2.2.1 Regulatory Framework in the U.S.
    • 2.2.2 Regulatory Framework in Europe
    • 2.2.3 Regulatory Framework in Asia-Pacific
      • 2.2.3.1 Japan
      • 2.2.3.2 China
  • 2.3 COVID-19's Impact on Cancer Diagnostic Market
  • 2.4 Supply Chain Analysis
    • 2.4.1 Key Entities in Supply Chain
  • 2.5 Pricing Analysis
  • 2.6 Comparative Analysis of Hematologic Malignancies Test by Different Parameters

3 Global Hematologic Malignancies Testing Market: Market Dynamics

  • 3.1 Impact Analysis
  • 3.2 Market Drivers
    • 3.2.1 Rising Incidence of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, and Leukemia Facilitating the Demand for Hematologic Malignancy Testing Kits and Services
    • 3.2.2 Increased Funding and Community Support for Early Detection and Treatment to Create a Demand for Hematologic Malignancy Testing Kits and Services
    • 3.2.3 Continuous Advancements in Hematologic Malignancy Testing
  • 3.3 Market Restraints
    • 3.3.1 Challenges in Integrating NGS into Clinical Practice for Hematologic Malignancies
    • 3.3.2 Unfavorable Reimbursement Scenario
  • 3.4 Market Opportunities
    • 3.4.1 Strategic Partnerships to Enhance Diagnostic Capabilities in Emerging Markets
    • 3.4.2 Leveraging AI for Enhanced Diagnostics in the Hematologic Malignancies Testing Market

4 Global Hematologic Malignancies Testing Market (by Product)

  • 4.1 Product Summary
  • 4.2 By Product
    • 4.2.1 Kits
      • 4.2.1.1 Gene Panels
      • 4.2.1.2 Molecular Clonality Testing
      • 4.2.1.3 Translocation Testing
      • 4.2.1.4 Mutation Testing
      • 4.2.1.5 Minimal Residual Testing
    • 4.2.2 Services

5 Global Hematologic Malignancies Testing Market (by Platform)

  • 5.1 Platform Summary
  • 5.2 By Platform
    • 5.2.1 Next-Generation Sequencing
      • 5.2.1.1 Polymerase Chain Reaction (PCR)
    • 5.2.2 Fluorescence In-Situ Hybridization
    • 5.2.3 Immunohistochemistry
    • 5.2.4 Flow Cytometry
    • 5.2.5 Other Platforms
      • 5.2.5.1 Cytogenetic Testing
      • 5.2.5.2 Microarray

6 Global Hematologic Malignancies Testing Market (by Diseases)

  • 6.1 Diseases Summary
  • 6.2 By Diseases
    • 6.2.1 Leukemia
    • 6.2.2 Lymphoma
    • 6.2.3 Multiple Myeloma
    • 6.2.4 Myeloproliferative Neoplasms
    • 6.2.5 Myelodysplastic Syndromes

7 Global Hematologic Malignancies Testing Market (by End User)

  • 7.1 End User Summary
  • 7.2 By End User
    • 7.2.1 Specialty Clinics and Hospitals
    • 7.2.2 Diagnostic Laboratories
    • 7.2.3 Reference Laboratories

8 Global Hematologic Malignancies Testing Market (By Region)

  • 8.1 Regional Summary
  • 8.2 Drivers and Restraints
  • 8.3 North America
    • 8.3.1 Regional Overview
    • 8.3.2 Driving Factors for Market Growth
    • 8.3.3 Factors Challenging the Market
    • 8.3.4 U.S.
    • 8.3.5 Canada
  • 8.4 Europe
    • 8.4.1 Regional Overview
    • 8.4.2 Driving Factors for Market Growth
    • 8.4.3 Factors Challenging the Market
    • 8.4.4 Germany
    • 8.4.5 U.K.
    • 8.4.6 Spain
    • 8.4.7 Italy
    • 8.4.8 France
    • 8.4.9 Denmark
    • 8.4.10 Rest-of-Europe
  • 8.5 Asia-Pacific
    • 8.5.1 Regional Overview
    • 8.5.2 Driving Factors for Market Growth
    • 8.5.3 Factors Challenging the Market
    • 8.5.4 China
    • 8.5.5 Japan
    • 8.5.6 India
    • 8.5.7 Australia
    • 8.5.8 South Korea
    • 8.5.9 Singapore
    • 8.5.10 Rest-of-Asia-Pacific
  • 8.6 Latin America
    • 8.6.1 Regional Overview
    • 8.6.2 Driving Factors for Market Growth
    • 8.6.3 Factors Challenging the Market
    • 8.6.4 Brazil
    • 8.6.5 Mexico
    • 8.6.6 Rest-of-Latin America
  • 8.7 Middle East and Africa
    • 8.7.1 Regional Overview
    • 8.7.2 Driving Factors for Market Growth
    • 8.7.3 Factors Challenging the Market
    • 8.7.4 K.S.A.
    • 8.7.5 U.A.E.
    • 8.7.6 South Africa
    • 8.7.7 Rest-of-Middle East and Africa

9 Global Hematologic Malignancies Testing Market - Competitive Benchmarking and Company Profiles

  • 9.1 Key Strategies and Development
    • 9.1.1 Partnerships, Alliances, and Business Expansions
    • 9.1.2 Regulatory and Legal Activities
    • 9.1.3 New Offerings
    • 9.1.4 Mergers and Acquisitions
  • 9.2 Market Share
  • 9.3 Company Profiles
    • 9.3.1 Abbott Laboratories
      • 9.3.1.1 Overview
      • 9.3.1.2 Top Products
      • 9.3.1.3 Top Competitors
      • 9.3.1.4 Top Customers
      • 9.3.1.5 Key Personnel
      • 9.3.1.6 Corporate Strategies
      • 9.3.1.7 Analyst View
    • 9.3.2 Adaptive Biotechnologies
      • 9.3.2.1 Overview
      • 9.3.2.2 Top Products
      • 9.3.2.3 Top Competitors
      • 9.3.2.4 Top Customers
      • 9.3.2.5 Key Personnel
      • 9.3.2.6 Corporate Strategies
      • 9.3.2.7 Analyst View
    • 9.3.3 ARUP Laboratories
      • 9.3.3.1 Overview
      • 9.3.3.2 Top Products
      • 9.3.3.3 Top Competitors
      • 9.3.3.4 Top Customers
      • 9.3.3.5 Key Personnel
      • 9.3.3.6 Analyst View
    • 9.3.4 Bio-Rad Laboratories, Inc.
      • 9.3.4.1 Overview
      • 9.3.4.2 Top Products
      • 9.3.4.3 Top Competitors
      • 9.3.4.4 Top Customers
      • 9.3.4.5 Key Personnel
      • 9.3.4.6 Analyst View
    • 9.3.5 F. Hoffmann-La Roche Ltd.
      • 9.3.5.1 Overview
      • 9.3.5.2 Top Products
      • 9.3.5.3 Top Competitors
      • 9.3.5.4 Key Customers
      • 9.3.5.5 Key Personnel
      • 9.3.5.6 Corporate Strategies
      • 9.3.5.7 Analyst View
    • 9.3.6 ICON plc
      • 9.3.6.1 Overview
      • 9.3.6.2 Top Products
      • 9.3.6.3 Top Competitors
      • 9.3.6.4 Top Customers
      • 9.3.6.5 Key Personnel
      • 9.3.6.6 Analyst View
    • 9.3.7 Illumina, Inc.
      • 9.3.7.1 Overview
      • 9.3.7.2 Top Products
      • 9.3.7.3 Top Competitors
      • 9.3.7.4 Top Competitors
      • 9.3.7.5 Key Personnel
      • 9.3.7.6 Corporate Strategies
      • 9.3.7.7 Analyst View
    • 9.3.8 Invitae Corporation
      • 9.3.8.1 Overview
      • 9.3.8.2 Top Products
      • 9.3.8.3 Top Competitors
      • 9.3.8.4 Top Customers
      • 9.3.8.5 Key Personnel
      • 9.3.8.6 Corporate Strategies
      • 9.3.8.7 Analyst View
    • 9.3.9 Invivoscribe Inc.
      • 9.3.9.1 Overview
      • 9.3.9.2 Top Products
      • 9.3.9.3 Top Competitors
      • 9.3.9.4 Top Customers
      • 9.3.9.5 Key Personnel
      • 9.3.9.6 Analyst View
    • 9.3.10 Laboratory Corporation of America Holdings
      • 9.3.10.1 Overview
      • 9.3.10.2 Top Products
      • 9.3.10.3 Top Competitors
      • 9.3.10.4 Top Customers
      • 9.3.10.5 Key Personnel
      • 9.3.10.6 Corporate Strategies
      • 9.3.10.7 Analyst View
    • 9.3.11 NeoGenomics Laboratories
      • 9.3.11.1 Overview
      • 9.3.11.2 Top Products
      • 9.3.11.3 Top Competitors
      • 9.3.11.4 Top Customers
      • 9.3.11.5 Key Personnel
      • 9.3.11.6 Analyst View
    • 9.3.12 OHSU's Knight Diagnostic Laboratories
      • 9.3.12.1 Overview
      • 9.3.12.2 Top Products
      • 9.3.12.3 Top Competitors
      • 9.3.12.4 Top Customers
      • 9.3.12.5 Key Personnel
      • 9.3.12.6 Analyst View
    • 9.3.13 QIAGEN N.V.
      • 9.3.13.1 Overview
      • 9.3.13.2 Top Products
      • 9.3.13.3 Top Competitors
      • 9.3.13.4 Top Customers
      • 9.3.13.5 Key Personnel
      • 9.3.13.6 Corporate Strategies
      • 9.3.13.7 Analyst View
    • 9.3.14 Quest Diagnostics
      • 9.3.14.1 Overview
      • 9.3.14.2 Top Products
      • 9.3.14.3 Top Competitors
      • 9.3.14.4 Top Customers
      • 9.3.14.5 Key Personnel
      • 9.3.14.6 Corporate Strategies
      • 9.3.14.7 Analyst View
    • 9.3.15 Sysmex Corporation
      • 9.3.15.1 Overview
      • 9.3.15.2 Top Products
      • 9.3.15.3 Top Competitors
      • 9.3.15.4 Top Customers
      • 9.3.15.5 Key Personnel
      • 9.3.15.6 Analyst View
    • 9.3.16 Tempus Labs, Inc
      • 9.3.16.1 Overview
      • 9.3.16.2 Top Products
      • 9.3.16.3 Top Competitors
      • 9.3.16.4 Top Customers
      • 9.3.16.5 Key Personnel
      • 9.3.16.6 Analyst View
    • 9.3.17 Bio-Techne
      • 9.3.17.1 Overview
      • 9.3.17.2 Top Products
      • 9.3.17.3 Top Competitors
      • 9.3.17.4 Top Customers
      • 9.3.17.5 Key Personnel
      • 9.3.17.6 Analyst View
    • 9.3.18 DiaSorin S.p.A
      • 9.3.18.1 Overview
      • 9.3.18.2 Top Products
      • 9.3.18.3 Top Competitors
      • 9.3.18.4 Top Customers
      • 9.3.18.5 Key Personnel
      • 9.3.18.6 Corporate Strategies
      • 9.3.18.7 Analyst View
    • 9.3.19 Foundation Medicine, Inc.
      • 9.3.19.1 Overview
      • 9.3.19.2 Top Products
      • 9.3.19.3 Top Competitors
      • 9.3.19.4 Top Customers
      • 9.3.19.5 Key Personnel
      • 9.3.19.6 Analyst View
    • 9.3.20 Thermo Fisher Scientific, Inc.
      • 9.3.20.1 Overview
      • 9.3.20.2 Top Products
      • 9.3.20.3 Top Competitors
      • 9.3.20.4 Top Customers
      • 9.3.20.5 Key Personnel
      • 9.3.20.6 Corporate Strategies
      • 9.3.20.7 Analyst View
    • 9.3.21 ELITech Group
      • 9.3.21.1 Overview
      • 9.3.21.2 Top Products
      • 9.3.21.3 Top Competitors
      • 9.3.21.4 Top Customers
      • 9.3.21.5 Analyst View
    • 9.3.22 Vela Diagnostics
      • 9.3.22.1 Overview
      • 9.3.22.2 Top Products
      • 9.3.22.3 Top Competitors
      • 9.3.22.4 Top Customers
      • 9.3.22.5 Key Personnel
      • 9.3.22.6 Analyst View
    • 9.3.23 Amoy Diagnostics Co., Ltd.
      • 9.3.23.1 Overview
      • 9.3.23.2 Top Products
      • 9.3.23.3 Top Competitors
      • 9.3.23.4 Top Customers
      • 9.3.23.5 Key Personnel
      • 9.3.23.6 Analyst View
    • 9.3.24 Integrated DNA Technologies, Inc.
      • 9.3.24.1 Overview
      • 9.3.24.2 Top Products
      • 9.3.24.3 Top Competitors
      • 9.3.24.4 Top Customers
      • 9.3.24.5 Key Personnel
      • 9.3.24.6 Corporate Strategies
      • 9.3.24.7 Analyst View

10 Research Methodology

  • 10.1 Data Sources
    • 10.1.1 Primary Data Sources
    • 10.1.2 Secondary Data Sources
    • 10.1.3 Data Triangulation

List of Figures

  • Figure 1: Global Hematologic Malignancies Testing Market, $Million, 2024, 2028 and 2033
  • Figure 2: Global Hematologic Malignancies Testing Market (by Region), $Million, 2023, 2027, and 2033
  • Figure 3: Global Hematologic Malignancies Testing Market (by Product), $Million, 2023, 2027, and 2033
  • Figure 4: Global Hematologic Malignancies Testing Market (by Platform), $Million, 2023, 2027, and 2033
  • Figure 5: Global Hematologic Malignancies Testing Market (by Disease), $Million, 2023, 2027, and 2033
  • Figure 6: Global Hematologic Malignancies Testing Market (by End User), $Million, 2023, 2027, and 2033
  • Figure 7: Global Hematologic Malignancies Testing Market, Recent Developments
  • Figure 8: Classification of Hematologic Malignancies
  • Figure 9: Global Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 10: Global Hematologic Malignancies Testing Market Vs TAM, 2022-2033
  • Figure 11: Share of Partnerships, Alliances, and Business Expansions vs. Other Strategies
  • Figure 12: Some of the Key Partnerships, Alliances, and Business Expansions and their Impact on the Global Sequencing Market
  • Figure 13: Workflow for the Product Approval in the Market
  • Figure 14: Workflow for the IVD Product Approval
  • Figure 15: Workflow for Medical Device Regulations
  • Figure 16: Workflow for Market Approval of In-Vitro Diagnostics in China
  • Figure 17: Medical Research Cycle Interruption during the COVID-19 Pandemic
  • Figure 18: Hematologic Malignancies Testing Supply Chain Analysis
  • Figure 19: Global Incidence of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, and Leukemia, 2022-2050
  • Figure 20: Some of the Funding for Hematologic Malignancy Ecosystem
  • Figure 21: U.S. Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 22: U.S. Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 23: Canada Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 24: Canada Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 25: Germany Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 26: Germany Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 27: U.K. Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 28: U.K. Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 29: Spain Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 30: Spain Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 31: Italy Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 32: Italy Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 33: France Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 34: France Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 35: Denmark Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 36: Denmark. Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 37: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 38: China Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 39: China Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 40: Japan Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 41: Japan Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 42: India Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 43: Australia Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 44: Australia Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 45: South Korea Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 46: South Korea Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 47: Singapore Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 48: Singapore Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 49: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 50: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 51: Brazil Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 52: Brazil Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 53: Mexico Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 54: Mexico Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 55: Rest-of-Latin America Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 56: Rest-of-Latin America Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 57: K.S.A. Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 58: K.S.A. Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 59: U.A.E. Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 60: U.A.E. Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 61: South Africa Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 62: South Africa Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 63: Rest-of-Middle East and Africa Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Figure 64: Rest-of-Middle East and Africa Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
  • Figure 65: Partnerships, Alliances, and Business Expansions Activities, January 2020-May 2024
  • Figure 66: Regulatory and Legal Activities, January 2020-May 2024
  • Figure 67: New Offerings, January 2020-May 2024
  • Figure 68: Mergers and Acquisitions, January 2020-May 2024
  • Figure 69: Global Hematologic Malignancies Testing Market, Market Share (by Company)
  • Figure 70: Data Triangulation
  • Figure 71: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global Hematologic Malignancies Testing Market, Market Opportunities
  • Table 3: Diagnostic Tests for Hematologic Malignancies
  • Table 4: Current and Future Impact of Trends
  • Table 5: Registration Criteria for IVDs as per the CFDA
  • Table 6: Effect of COVID-19 on Cancer Care throughout the World
  • Table 7: Pricing Analysis (by Platform Testing)
  • Table 8: Comparative Analysis of Hematologic Malignancies Test
  • Table 9: Impact Analysis of Market Drivers
  • Table 10: Impact Analysis of Market Restraints
  • Table 11: Impact Analysis of Market Opportunities
  • Table 12: Global Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 13: Global Hematologic Malignancies Testing Market (by Kits), $Million, 2022-2033
  • Table 14: Global Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 15: Global Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 16: Global Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 17: Global Hematologic Malignancies Testing Market (by Region), $Million, 2022-2033
  • Table 18: Global Hematologic Malignancies Testing Market (by Country), $Million, 2022-2033
  • Table 19: North America Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 20: North America Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 21: North America Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 22: North America Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 23: U.S. Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 24: U.S. Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 25: U.S. Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 26: U.S. Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 27: Canada Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 28: Canada Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 29: Canada Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 30: Canada Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 31: Canada Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 32: Canada Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 33: Canada Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 34: Europe Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 35: Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 36: Europe Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 37: Europe Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 38: Germany Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 39: Germany Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 40: Germany Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 41: Germany Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 42: Germany Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 43: Germany Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 44: Germany Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 45: U.K. Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 46: U.K. Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 47: U.K. Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 48: U.K. Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 49: U.K. Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 50: U.K. Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 51: U.K. Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 52: Spain Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 53: Spain Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 54: Spain Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 55: Spain Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 56: Spain Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 57: Spain Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 58: Spain Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 59: Italy Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 60: Italy Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 61: Italy Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 62: Italy Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 63: Italy Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 64: Italy Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 65: Italy Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 66: France Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 67: France Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 68: France Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 69: France Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 70: France Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 71: France Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 72: France Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 73: Denmark Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 74: Denmark Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 75: Denmark Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 76: Denmark Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 77: Denmark Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 78: Denmark Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 79: Denmark Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 80: Rest-of-Europe Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Table 81: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 82: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 83: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 84: Rest-of-Europe Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 85: Rest-of-Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 86: Rest-of-Europe Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 87: Rest-of-Europe Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 88: Asia-Pacific Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 89: Asia-Pacific Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 90: Asia-Pacific Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 91: Asia-Pacific Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 92: China Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 93: China Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 94: China Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 95: China Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 96: China Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 97: China Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 98: China Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 99: Japan Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 100: Japan Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 101: Japan Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 102: Japan Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 103: Japan Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 104: Japan Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 105: Japan Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 106: India Hematologic Malignancies Testing Market, $Million, 2022-2033
  • Table 107: India Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 108: India Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 109: India Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 110: India Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 111: India Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 112: India Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 113: India Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 114: Australia Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 115: Australia Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 116: Australia Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 117: Australia Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 118: Australia Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 119: Australia Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 120: Australia Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 121: South Korea Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 122: South Korea Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 123: South Korea Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 124: South Korea Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 125: South Korea Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 126: South Korea Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 127: South Korea Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 128: Singapore Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 129: Singapore Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 130: Singapore Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 131: Singapore Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 132: Singapore Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 133: Singapore Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 134: Singapore Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 135: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 136: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 137: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 138: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 139: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 140: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 141: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 142: Latin America Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 143: Latin America Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 144: Latin America Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 145: Latin America Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 146: Brazil Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 147: Brazil Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 148: Brazil Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 149: Brazil Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 150: Brazil Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 151: Brazil Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 152: Brazil Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 153: Mexico Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 154: Mexico Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 155: Mexico Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 156: Mexico Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 157: Mexico Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 158: Mexico Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 159: Mexico Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 160: Rest-of-Latin America Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 161: Rest-of-Latin America Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 162: Rest-of-Latin America Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 163: Rest-of-Latin America Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 164: Rest-of-Latin America Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 165: Rest-of-Latin America Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 166: Rest-of-Latin America Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 167: Middle East and Africa Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 168: Middle East and Africa Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 169: Middle East and Africa Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 170: Middle East and Africa Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 171: K.S.A. Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 172: K.S.A. Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 173: K.S.A. Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 174: K.S.A. Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 175: K.S.A. Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 176: K.S.A. Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 177: K.S.A. Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 178: U.A.E. Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 179: U.A.E. Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 180: U.A.E. Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 181: U.A.E. Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 182: U.A.E. Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 183: U.A.E. Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 184: U.A.E. Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 185: South Africa Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 186: South Africa Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 187: South Africa Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 188: South Africa Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 189: South Africa Hematologic Malignancies Testing
  • Table 190: South Africa Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 191: South Africa Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 192: Rest-of-Middle East and Africa Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
  • Table 193: Rest-of-Middle East and Africa Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
  • Table 194: Rest-of-Middle East and Africa Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
  • Table 195: Rest-of-Middle East and Africa Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
  • Table 196: Rest-of-Middle East and Africa Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
  • Table 197: Rest-of-Middle East and Africa Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
  • Table 198: Rest-of-Middle East and Africa Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
  • Table 199: Global Hematologic Malignancies Testing Market, Key Development Analysis, January 2020-May 2024